Cefadroxil
Classification: BATC code: J01DB05
Summary
Large controlled studies on differences between men and women regarding efficacy, safety and pharmacokinetics of cefadroxil are lacking.
The present evidence concerning differences between men and women is limited and do not motivate differentiation in dosing or treatment.
Additional information
Pharmacokinetics and dosing
No studies with a clinically relevant sex analysis regarding the pharmacokinetics or dosing of cefadroxil have been found.
Effects
In a trial with a three-day oral treatment with cefadroxil 1 g daily in elderly patients with bacteriuri (2 men and 11 women on cefadroxil) only two women had negative urine cultures [1]. The clinical significance of this is uncertain.
Resistance patterns for pathogens often differ between populations. A study in Swedish children (494 boys, 512 girls; <2 years old) between the years 1994-2003 found that the resistance to cefadroxil in the entire population by E. coli was very low (<1%) while enterococci showed total resistance [2].
Adverse effects
No studies with a clinically relevant sex analysis regarding adverse effects of cefadroxil have been found.
Reproductive health issues
Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).
Updated: 2020-08-28
Date of litterature search: 2016-02-24
References
- Tzias V, Dontas AS, Petrikkos G, Papapetropoulou M, Dracopoulos J, Giamarellou H. Three-day antibiotic therapy in bacteriuria of old age. J Antimicrob Chemother. 1990;26:705-11. PubMed
- Swerkersson S, Jodal U, Åhrén C, Hansson S. Urinary tract infection in small outpatient children: the influence of age and gender on resistance to oral antimicrobials. Eur J Pediatr. 2014;173:1075-81. PubMed
- Socialstyrelsens statistikdatabas . Stockholm: Socialstyrelsen. 2015 [cited 2016-03-14.] Socialstyrelsens statistikdatabas
Reviewed by: Mia von Euler
Approved by: Karin Schenck-Gustafsson